Academic Journal
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer:evaluation of the randomised DAHANCA 6&7 trial
| العنوان: | The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer:evaluation of the randomised DAHANCA 6&7 trial |
|---|---|
| المؤلفون: | Lassen, Pernille, Eriksen, Jesper Grau, Krogdahl, Annelise, Therkildsen, Marianne Hamilton, Ulhøi, Benedicte P, Overgaard, Marie, Specht, Lena, Andersen, Elo, Johansen, Jørgen, Andersen, Lisbeth J, Grau, Cai, Overgaard, Jens |
| المصدر: | Lassen , P , Eriksen , J G , Krogdahl , A , Therkildsen , M H , Ulhøi , B P , Overgaard , M , Specht , L , Andersen , E , Johansen , J , Andersen , L J , Grau , C , Overgaard , J & Danish Head and Neck Cancer Group (DAHANCA) 2011 , ' The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer : evaluation of the randomised DAHANCA 6 &7 trial ' , Radiotherapy & Oncology , vol. 100 , no. 1 , pp. 49-55 .... |
| سنة النشر: | 2011 |
| المجموعة: | University of Southern Denmark: Research Output / Syddansk Universitet |
| الوصف: | BACKGROUND AND PURPOSE: Tumour HPV-positivity is a favourable prognostic factor in the radiotherapy of HNSCC, but the optimal radiotherapy regimen for HPV-positive HNSCC is not yet defined. Reducing overall treatment time is known to improve outcome in the radiotherapy of HNSCC as was also demonstrated in the randomised DAHANCA 6&7 trial. We aimed to assess the influence of tumour HPV-status, expressed by p16, on the response to accelerated fractionated radiotherapy in HNSCC through evaluation of the DAHANCA 6&7 trial. MATERIALS AND METHODS: Immunohistochemical detection of HPV-associated p16-expression was performed on FFPE-pre-treatment tumour-tissues from 794 patients enrolled in the DAHANCA 6&7 trial. The influence of tumour p16-status on loco-regional tumour control and survival as a function of fractionation schedule (5Fx/week vs 6Fx/week) was evaluated 5years after the completion of radiotherapy. RESULTS: The significant and independent prognostic value of tumour p16-positivity in HNSCC radiotherapy was confirmed, with adjusted hazard ratios (HR) of 0.58 [0.43-0.78], 0.47 [0.33-0.67] and 0.54 [0.42-0.68] for loco-regional control, disease-specific and overall survival, respectively. Accelerated radiotherapy significantly improved loco-regional tumour control compared to conventional radiotherapy, adjusted HR: 0.73 [0.59-0.92] and the benefit of the 6Fx/week regimen was observed both in p16-positive (HR: 0.56 [0.33-0.96]) as well as in p16-negative tumours (HR: 0.77 [0.60-0.99]). Disease-specific survival was also significantly improved with accelerated radiotherapy in the group of p16-positive tumours (adjusted HR: 0.43 [0.22-0.82]). CONCLUSION: Accelerated radiotherapy significantly improves outcome in HNSCC compared to conventional fractionation. The observed benefit is independent of tumour p16-status and the use of a moderately accelerated radiotherapy regimen seems advantageous also for HPV/p16-positive HNSCC. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://portal.findresearcher.sdu.dk/da/publications/4d8f19f3-c594-45f1-911f-cea7695bb7c5 |
| DOI: | 10.1016/j.radonc.2011.02.010 |
| الاتاحة: | https://portal.findresearcher.sdu.dk/da/publications/4d8f19f3-c594-45f1-911f-cea7695bb7c5 https://doi.org/10.1016/j.radonc.2011.02.010 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.86A54569 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.radonc.2011.02.010 |
|---|